Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$81.96
-$2.13(-2.60%)
At close: 4:00 PM EDT
$81.96
-$2.13(-2.60%)
Day’s Range― - ―
52-Week Range$20.10 - $97.97
Previous Close$79.83
Volume47.21K
Average Volume (3M)34.17K
Market Cap
$252.99M
Enterprise Value$195.32
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 05, 2026EPS Estimate
-2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume44,977
30 Day Avg. Volume34,168
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$196.67Price Target Upside139.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.32
Revenue Forecast (FY)$352.00K
Bulls Say, Bears Say
Bulls Say
Cash Runway And FundingThe substantial cash balance and stated runway reduce near-term financing pressure, allowing Sol-Gel to complete its pivotal trial and advance commercialization without immediately relying on additional capital.
Lead Asset IP Protection And Clinical ProgressA late-stage asset with long-dated patent protection could support durable economics if the trial succeeds. The approaching readout creates a defined catalyst while the extended IP term protects future commercialization potential.
Pipeline And Partnership ExpansionInternational licensing and additional patidegib studies broaden the company’s potential revenue base beyond one indication. Successful expansion could improve platform utilization and create royalty or product opportunities over time.
Bears Say
High Revenue Volatility And Ongoing LossesThe sharp revenue decline shows that reported performance remains vulnerable to nonrecurring items and limited product scale. Continued net losses indicate that commercial revenue has not yet established a dependable earnings base.
Eroding Equity Base And Prior Cash BurnLow debt limits leverage risk, but cumulative losses have reduced shareholder capital and historical cash burn highlights funding dependence. The balance sheet remains exposed if operating improvements fail to persist.
Clinical And Commercialization Concentration RiskNear-term strategic value is concentrated in one pivotal program and a relatively narrow initial indication. Trial failure, delay, or slower adoption could materially limit revenue, while later expansion studies remain unproven.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $20.10 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $252.99M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Aug 20, 2026. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$2.36 by $1.23.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -2.2.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,268,991 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -$1.13 in its last earnings report, beating expectations of -$2.36. Following the earnings report the stock price went down -0.121%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$196.67 (139.95% Upside)
$196.67 (139.95% Upside)
Blogger Sentiment
Bullish
SLGL Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth $331.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.9%
Last 30 Days ▲ 22.1%
Last 30 Days ▲ 22.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
637.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.76%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$196.67
▲(139.95% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
15.60% Insiders
0.04% Mutual Funds
38.24% Other Institutional Investors
45.21% Public Companies and
Individual Investors